Skip to main content
SpringerLink
Log in

Coverage is key when selecting insurance in rare diseases

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Robinson SW, et al. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans. Journal of Managed Care Pharmacy 20: 997-1004, No. 10, Oct 2014. Available from: URL: http://doi.org/20142010.997-1004

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coverage is key when selecting insurance in rare diseases. PharmacoEcon Outcomes News 714, 17 (2014). https://doi.org/10.1007/s40274-014-1638-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1638-9

Search

Navigation